Briefing
COBRA: ctDNA as a predictive biomarker for adjuvant chemotherapy in stage IIA colon cancer
Phase 2/3 trial of whether ctDNA detection after resection of stage IIA colon cancer identifies patients who benefit from adjuvant chemotherapy. ClinicalTrials.gov lists the study as active, not recruiting.
- Design: Phase 2/3 · Active, not recruiting